Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91].

Authors
Category Primary study
JournalSchizophrenia Research
Year 2022
This article has no abstract
Epistemonikos ID: 7761a5bdaa2648eaa03814117ad19dae48b88c27
First added on: May 09, 2025